Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $29 to $32.
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $29 to $32.